KEGG   DRUG: Dolutegravir sodium and rilpivirine hydrochloride
Entry
D11282            Mixture   Drug                                   
Name
Dolutegravir sodium and rilpivirine hydrochloride;
Juluca (TN)
Product
JULUCA (ViiV Healthcare Company)
Component
Dolutegravir sodium [DR:D10113], Rilpivirine hydrochloride [DR:D09958]
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
 DG02924  UGT substrate
  DG03183  UGT1A1 substrate
Transporter inhibitor
 DG02863  SLC22A2 inhibitor
 DG02864  SLC47A1 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AR21
Product: D11282<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A; it is also an inhibitor of OCT2 and MATE1.
Rilpivirine is primarily metabolized by CYP3A.
Target
HIV-1 reverse transcriptase [KO:K24802]
HIV-1 integrase [KO:K24803]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], UGT1A1 [HSA:54658]
Interaction
Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [hsa:55244]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR21 Dolutegravir and rilpivirine
      D11282  Dolutegravir sodium and rilpivirine hydrochloride <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Dolutegravir Sodium/ Rilpivirine
    D11282  Dolutegravir sodium and rilpivirine hydrochloride
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D11282  Dolutegravir sodium and rilpivirine hydrochloride
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D11282  Dolutegravir sodium and rilpivirine hydrochloride
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   D11282  Dolutegravir sodium and rilpivirine hydrochloride
  DG02924  UGT substrate
   DG03183  UGT1A1 substrate
    D11282  Dolutegravir sodium and rilpivirine hydrochloride
 Transporter inhibitor
  DG02863  SLC22A2 inhibitor
   D11282  Dolutegravir sodium and rilpivirine hydrochloride
  DG02864  SLC47A1 inhibitor
   D11282  Dolutegravir sodium and rilpivirine hydrochloride
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D11282  Dolutegravir sodium and rilpivirine hydrochloride
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV integrase inhibitor
    D11282  Dolutegravir sodium and rilpivirine hydrochloride <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11282
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11282
 Drug transporters
  D11282
Other DBs
PubChem: 384585260
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system